Globally, these results confirmed that a combined therapy with an inhibitor of MDM2/p53 complex and an inhibitor of the AKT/mTOR pathway could be a useful anti-proliferative strategy in GBM cells. The gene discussed is MDM2; the disease is glioblastoma.